Quick rundown of phase 1 data. The phase 3 is going to be a 100 microgram dose. It produces antibodies, which will provide short term protection but we have no idea about the long term t-cell production. The phase 1 and phase 2 will continue to have tests to measure long term protection as we move through the phase 3 trial. One person had to quit the study due to skin rashes and the most severe side effects cited in the study were localized pain. As the professional says in the video, there could still be side effects that pop when it is given to 30k people that did not show up in the very small phase 1. My job places me at high risk for a high dose infection so I joined the study because my country already views me as a lab rat, why not get the antibodies?